HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment.

AbstractBACKGROUND:
Ischemic stroke is one of the leading causes of mortality and morbidity in the world and effective neuroprotectants are yet to be developed. Recent studies have demonstrated excellent neuroprotective effects of a bivalent enkephalin opioid agonist, biphalin in multiple stroke models.
METHODS:
The purpose of this study is to evaluate novel multifunctional enkephalin-fentanyl opioid agonists, LYS436, LYS739 and LYS416 for their neuroprotective potential using in vitro and in vivo ischemic stroke models and to compare the effect to that of biphalin.
RESULTS:
In general, all non-selective opioid agonists significantly decreased neuronal cell death and levels of reactive oxygen species in primary neurons subjescted to hypoxia-aglycemia/re-oxygenation or NMDA neurotoxicity. Fluorinated enkephalin-fentanyl conjugate, LYS739 showed enhanced neuroprotection in both in vitro models compared to biphalin. Based on further in vitro screening and comparative studies to biphalin, LYS739 was selected as a lead for in vivo experimentation. A mouse middle cerebral artery occlusion (MCAO) stroke model was utilized to study biphalin and the lead analog, LYS739. Both agonists significantly decreased brain infarct and edema ratios compared to saline treated group. Neurological impairment after stroke was statistically significantly improved in terms of neurological score and locomotor activities with LYS739 and biphalin treatment. Importantly, LYS739 and biphalin demonstrated better neuroprotection compared to fentanyl, and this effect was reversed by non-selective opioid antagonist naltrexone.
CONCLUSION:
In summary, the results of this study suggest that the multifunctional fluorinated enkephalin analog, LYS739 can be considered as a potential lead for ischemic stroke research and may provide advantages given the multimeric peptide-opiate structure.
AuthorsMohammad Rashedul Islam, Li Yang, Yeon Sun Lee, Victor J Hruby, Vardan T Karamyan, Thomas J Abbruscato
JournalCurrent pharmaceutical design (Curr Pharm Des) Vol. 22 Issue 42 Pg. 6459-6468 ( 2016) ISSN: 1873-4286 [Electronic] United Arab Emirates
PMID27510489 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright© Bentham Science Publishers; For any queries, please email at [email protected].
Chemical References
  • Analgesics, Opioid
  • Enkephalins
  • Neuroprotective Agents
  • Fentanyl
Topics
  • Analgesics, Opioid (chemistry, pharmacology)
  • Animals
  • Brain Ischemia (drug therapy)
  • Dose-Response Relationship, Drug
  • Enkephalins (chemistry, pharmacology)
  • Fentanyl (chemistry, pharmacology)
  • Male
  • Mice
  • Molecular Conformation
  • Neurons (drug effects)
  • Neuroprotective Agents (chemistry, pharmacology)
  • Stroke (drug therapy)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: